A meta-analysis by the Cardiovascular Research Foundation, and published in the June 15 edition of Circulation, of 56 studies that covered 190,000 patients revealed unambiguous benefits for use of drug-eluting stents (DES) instead of bare metal stents.
- DES resulted in a reduction in death from no difference (meta-analysis of 22 randomized trials) to a 22% reduction (34 study observational meta-analysis)
- DES resulted in a reduction in MI from no difference (meta-analysis of 22 randomized trials) to a 13% reduction (34 study observational meta-analysis)
- DES yielded a greater than 50% decrease in subsequent target vessel revascularization procedures
Study authors indicated that these findings are consistent with both on-label and off-label use of DES.
Drug eluting stents represent a $4.7 billion worldwide market, while the bare metal stents market stands at $2.7 billion. See the MedMarket Diligence Report #C245, "Worldwide Drug-Eluting, Bare Metal and Other Coronary Stents Market, 2008-2017." (Published May 2009.)